These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33195136)

  • 1. Potential Benefits of Allogeneic Haploidentical Adipose Tissue-Derived Stromal Vascular Fraction in a Hutchinson-Gilford Progeria Syndrome Patient.
    Pak J; Lee JH; Jeon JH; Kim YB; Jeong BC; Lee SH
    Front Bioeng Biotechnol; 2020; 8():574010. PubMed ID: 33195136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
    Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
    Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
    Finley J
    Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS.
    Denecke J; Brune T; Feldhaus T; Robenek H; Kranz C; Auchus RJ; Agarwal AK; Marquardt T
    Hum Mutat; 2006 Jun; 27(6):524-31. PubMed ID: 16671095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo.
    Wenzel V; Roedl D; Gabriel D; Gordon LB; Herlyn M; Schneider R; Ring J; Djabali K
    Biol Open; 2012 Jun; 1(6):516-26. PubMed ID: 23213444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells.
    Egesipe AL; Blondel S; Lo Cicero A; Jaskowiak AL; Navarro C; Sandre-Giovannoli A; Levy N; Peschanski M; Nissan X
    NPJ Aging Mech Dis; 2016; 2():16026. PubMed ID: 28721276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense-Based Progerin Downregulation in HGPS-Like Patients' Cells.
    Harhouri K; Navarro C; Baquerre C; Da Silva N; Bartoli C; Casey F; Mawuse GK; Doubaj Y; Lévy N; De Sandre-Giovannoli A
    Cells; 2016 Jul; 5(3):. PubMed ID: 27409638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes.
    Moulson CL; Fong LG; Gardner JM; Farber EA; Go G; Passariello A; Grange DK; Young SG; Miner JH
    Hum Mutat; 2007 Sep; 28(9):882-9. PubMed ID: 17469202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
    Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
    Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
    Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
    Eisch V; Lu X; Gabriel D; Djabali K
    Oncotarget; 2016 Apr; 7(17):24700-18. PubMed ID: 27015553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
    McClintock D; Gordon LB; Djabali K
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
    Villa-Bellosta R; Rivera-Torres J; Osorio FG; Acín-Pérez R; Enriquez JA; López-Otín C; Andrés V
    Circulation; 2013 Jun; 127(24):2442-51. PubMed ID: 23690466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
    Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hutchinson-Gilford progeria syndrome.
    Pollex RL; Hegele RA
    Clin Genet; 2004 Nov; 66(5):375-81. PubMed ID: 15479179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
    Hamczyk MR; Andrés V
    Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MG132 Induces Progerin Clearance and Improves Disease Phenotypes in HGPS-like Patients' Cells.
    Harhouri K; Cau P; Casey F; Guedenon KM; Doubaj Y; Van Maldergem L; Mejia-Baltodano G; Bartoli C; De Sandre-Giovannoli A; Lévy N
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of MnTBAP and Baricitinib Treatment on Hutchinson-Gilford Progeria Fibroblasts.
    Vehns E; Arnold R; Djabali K
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.